In many pharmacies, small mint-sized tablets sit quietly beside cough drops and vitamins. They promise relief from cravings, offering smokers a measured step away from tobacco. For years, nicotine lozenges have occupied a curious space—part medicine, part everyday product—available across counters that range from pharmacies to ordinary retail shops.
But policies sometimes evolve in response to changing habits and new concerns. In India, health authorities are now considering a subtle yet significant shift: moving nicotine lozenges out of general retail spaces and restricting their sale primarily to licensed pharmacies.
The proposal reflects a growing unease about how easily nicotine products can reach unintended users.
Nicotine lozenges are designed as smoking-cessation aids. They release controlled amounts of nicotine that help reduce withdrawal symptoms for people trying to quit cigarettes. Similar therapies—such as nicotine gum and patches—have been widely used around the world and are often recommended as part of structured quitting programs.
However, regulators in India are increasingly concerned that lozenges, particularly lower-dose versions such as 2-milligram tablets, may be circulating beyond their intended purpose.
Under current rules, certain nicotine lozenges fall under exemptions that allow them to be sold in general retail outlets without the same licensing requirements applied to pharmaceutical products. This means they can sometimes be found in convenience shops or small stores rather than exclusively in pharmacies.
Health authorities now appear ready to revisit that exemption.
According to recent reports, policymakers are considering removing nicotine lozenges from this category, effectively requiring that retailers obtain a drug sales license to sell them. If implemented, the change would move sales primarily into pharmacies and other regulated medical outlets.
The reasoning, officials suggest, is partly preventive. Regulators worry that easy availability in ordinary stores may allow access among minors or individuals who do not use tobacco but experiment with nicotine products.
Nicotine itself remains a highly addictive substance. Even when delivered through smoking-cessation tools, its use is generally intended to be temporary and guided by structured programs that gradually reduce dosage.
Experts in tobacco control often emphasize that nicotine replacement therapies can be effective when used correctly. Yet they also acknowledge that unsupervised use may blur the line between treatment and consumption.
By placing lozenges behind pharmacy counters, policymakers hope the products would remain accessible for smokers who want to quit while limiting casual or recreational use.
The discussion also unfolds within a broader context of nicotine regulation in India. The country has already taken a firm stance against some emerging nicotine products, including electronic cigarettes, which remain banned nationwide.
Public health authorities have argued that stricter oversight of nicotine products is necessary to prevent new forms of addiction, particularly among younger populations.
At the same time, many health experts caution that cessation aids should remain reasonably accessible to adult smokers trying to quit. Nicotine replacement therapies have long been recognized internationally as tools that can support tobacco cessation when used responsibly.
Balancing these two concerns—access for quitting, restriction for prevention—lies at the heart of the policy debate.
For now, the proposed change remains under consideration. If adopted, it would shift nicotine lozenges from ordinary shop counters to the more controlled environment of pharmacies.
In practical terms, the tablets themselves would remain available. The path to them, however, may soon pass through a pharmacist’s counter rather than the shelves of everyday stores.
AI Image Disclaimer Visuals are created with AI tools and are not real photographs.
Sources identified:
Mint The Economic Times Devdiscourse WHO Framework Convention on Tobacco Control reports Business Standard